On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
MondayOct 11, 2021 1:40 pm

QualityStocksNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples…

Continue Reading

MondayOct 11, 2021 1:26 pm

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

Continue Reading

MondayOct 11, 2021 1:08 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale researchers, psilocybin has been found to counteract symptoms of depression (https://ibn.fm/NCORl). “Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reads a recent article quoting a Yale Daily News publication titled “Yale Researchers Discover Healing Effects of Psychedelic Drug.” In the piece published…

Continue Reading

MondayOct 11, 2021 12:11 pm

QualityStocksNewsBreaks – PlantX Life Inc.’s (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Unveiling of Squamish ‘XMarket’ to Feature Vegan Barbecue, New Mural and High-Profile Ambassadors

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has marked many recent achievements and is focused on completing several key milestones for a strong remainder of the 2021 fiscal year. Among these, PlantX is focused on an ongoing retail branding initiative to rename its existing brick-and-mortar stores as “XMarket.” The new identity intends to reflect the dynamic, interactive and diverse in-store experience provided by the company’s physical retail locations. Currently, PlantX has physical stores in British Columbia, Squamish, and Venice Beach, California, all of which will be re-branded as XMarket. “The official unveiling of XMarket in Squamish, British Columbia,…

Continue Reading

MondayOct 11, 2021 12:00 pm

QualityStocksNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Helping People Get Hearing Aids at Fraction of Cost

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer (“DTC”) hearing technology space, is committed to changing the lives of millions of Americans with hearing impairment, helping them get the hearing aids they need at a fraction of the cost set by traditional hearing clinics. “The costs of one hearing aid alone can range from $1,000 to as much as $6,000, not including additional expenses that can occur, such as hearing tests, follow-ups and ongoing support from healthcare professionals,” reads a recent article. One of the key drivers of these prohibitive costs is that consumers must…

Continue Reading

FridayOct 08, 2021 1:15 pm

QualityStocksNewsBreaks – Why DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) Is ‘One to Watch’

DigiMax Global (CSE: DIGI) (OTC: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals. The company’s core solutions include CryptoHawk AI — A deep learning AI solution (“SaaS”) that monitors and analyzes live select cryptocurrencies and financial markets; Cryptocurrency Hedge Fund — A long/short cryptocurrency hedge fund for high net worth, institutional and family office clients; Projected Personality Interpreter (“PPI”) — A solution utilizing AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services; and Navee Predict — An…

Continue Reading

FridayOct 08, 2021 12:37 pm

QualityStocksNewsBreaks – Sugarmade Inc. (SGMD) Committed to Becoming True ‘Farm-to-Door’ Cannabis Company

Sugarmade (OTC: SGMD), an innovator in the dynamic California cannabis sector, recently updated its current and prospective shareholders to cover key milestones in the company’s strategic plan. The update included details on its growing Nug Avenue operations and additional strides toward verticalizing its model through the acquisition of California cannabis licenses and potentially establishing commercial operations in the cannabis delivery market outside of the state of California. Sugarmade CEO Jimmy Chan described as “tangible” the strides the company continues to make toward a vertically integrated model. “Our long-term strategic vision is to establish the capacity to control all aspects of…

Continue Reading

FridayOct 08, 2021 12:13 pm

QualityStocksNewsBreaks – Simply Sonoma Primed to Benefit from Projected Billion-Dollar Growth of CBD Space

Simply Sonoma, a CBD company focused on building a reputation as a leader in plant-based medicinal health and beauty products, is poised to benefit from the projected billion-dollar growth of the CBD space. This is according to a recent article discussing analysis by Yahoo.finance in a publication titled “CBD Market to Grow to $16 Billion by 2026 — Should You Invest?” The article, which contains excerpts from the publication, reports that increasing awareness of CBD’s therapeutic benefits has influenced buyers to purchase cannabidiol (“CBD”) products, in turn influencing commercial retailers, including those in health and wellness sectors, to now focus…

Continue Reading

FridayOct 08, 2021 11:51 am

QualityStocksNewsBreaks – FingerMotion Inc. (FNGR) Poised as Ideal Partner in Post-Pandemic Insurance Space in China

FingerMotion (OTCQX: FNGR) is a technology company with core competencies in SMS/MMS services, mobile payment and recharge solutions, and big data insights. Following revelations that the pandemic posed a significant challenge to the adaptability and resilience of insurance companies and their management teams, Deloitte China proposed that insurers apply big data to facilitate product differentiation and build digital operational capabilities to ensure longevity post-pandemic. In this regard, FingerMotion appears poised as an ideal partner for insurers looking to implement Deloitte China’s proposals. Through its big data insights division (“Sapientus”), which provides behavioral analytics sourced from publicly available data, FNGR is…

Continue Reading

FridayOct 08, 2021 11:35 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered